

**SOLE SOURCE JUSTIFICATION FOR
ACQUISITIONS UNDER THE SIMPLIFIED ACQUISITION THRESHOLD
PR-ORD-20-01701**

1. In accordance with Federal Acquisition Regulation 13.106-1(b)(1), I hereby determine that the **TempO-SeqR Assay and Analysis** listed on **PR-ORD-20-01701** is available from only one source, and competition is precluded for the reasons indicated below. There are no substitutes available.

2. This acquisition is restricted to the following source:

Company: BioSpyder Technologies, Inc.

Company Address: 5922 Farnsworth Court, Suite 102, Carlsbad, CA 92008

Company Point of Contact and Phone Number: Bitu Mavaddat (1-760-476-1800)

3. The TempO-SeqR Assay and Analysis is estimated to cost \$20,213.70 and is required to be delivered 60 days after sample receipt.

This requirement is to provide targeted gene sequencing on a set of 90 liver samples using the TempO-Seq[®] whole-genome targeted sequencing assay. The assay service is a BioSpyder platform which involves targeted sequencing (whole genome to interrogate) that will assist in evaluating the toxicity of a single PFAS chemical.

4. Specific characteristics of the TempO-SeqR Assay and Analysis that limit the availability to a sole source are their unique targeted sequencing process and quantitate targeted transcripts, which allow for easy to follow workflow that does not require dedicated equipment. Only this suggested source can furnish the requirements, to the exclusion of other sources as TempO-Sequence Whole-Genome Rat Assay service is a BioSpyder platform that contains proprietary features.

5. Check and fill in all that are applicable:

☐ The material or service must be compatible in all aspects (form, fit, and function) with existing systems presently installed. The current equipment is *<insert description of current equipment>*, and the new item/service must coordinate, connect, or interface with the existing system by *<insert description of how the new item/service must coordinate or interface>*.

☒ A patent, copyright, proprietary data, or licensing agreement limits competition. The proprietary data are described as follows:

The TempO-Seq Assay and Analysis contains proprietary features as well as patented

technology.

☐ These are "direct replacement" parts/components for existing equipment.

☒ Other information to support a sole-source buy:

- a. A Notice of Intent (NOI) to Sole Source was posted in fedconnect.net from 29 July 2020 to 08 August 2020 and no responses were received.
- b. This NOI supports the Market Research conducted by the contract specialist that no other vendors are available to meet this requirement.

CERTIFICATION

I certify that statements checked and information provided above are complete and correct to the best of my knowledge. In accordance with FAR 13.106-1(b)(1), the facts of this acquisition preclude the use of full and open competition.

William Sahli

13 Aug 20

William Sahli
Contracting Officer

Date

KPBarton

Kathryn P. Barton
Branch Chief

8/18/2020

Date